Sanofi SA / Vigil Neuroscience, Inc.

Alzheimer's Disease (TREM2-targeted microglial modulation)

7.2M US cases/yr · $3.8B Global Alzheimer's disease-modifying therapy market, 2025 (anti-amyloid class: Leqembi + Kisunla launch revenue) · ~30% Proportion of late-onset Alzheimer's risk attributable to microglial/innate-immune pathways including TREM2 (GWAS-derived)

Disease Overview

Alzheimer's disease is the most common cause of dementia, affecting an estimated 7.2M Americans age 65+ in 2025 per the Alzheimer's Association, with prevalence projected to nearly double to 13.8M by 2060. The disease is characterized by amyloid-beta plaque deposition, tau neurofibrillary tangles, synaptic loss, and neuroinflammation driven by activated microglia. Genome-wide association studies have established variants in TREM2 (triggering receptor expressed on myeloid cells 2) as among the strongest genetic risk factors for late-onset Alzheimer's outside APOE4, with R47H and other loss-of-function variants elevating risk roughly 2-4 fold. TREM2 is the primary innate-immune receptor on microglia that orchestrates plaque containment, amyloid clearance, and neuroprotective microglial phenotypes. Boosting TREM2 signaling has emerged as a novel disease-modifying strategy complementary to amyloid-clearing antibodies (Leqembi, Kisunla). Vigil's VG-3927 is the first oral small-molecule TREM2 agonist to enter human studies, offering potential convenience and dose flexibility versus infused biologics. Annual US new AD diagnoses exceed 500,000 and total direct care cost exceeds $360B per Alzheimer's Association 2025 Facts & Figures.

Competitive Landscape

The Alzheimer's disease-modifying therapy landscape has shifted dramatically with FDA approvals of anti-amyloid monoclonal antibodies lecanemab (Leqembi, Eisai/Biogen, 2023 full approval) and donanemab (Kisunla, Eli Lilly, 2024). Both require IV infusion, carry ARIA (amyloid-related imaging abnormalities) risks, and deliver modest clinical slowing of cognitive decline (~27-35% on CDR-SB). TREM2-targeted biologics include Alector's AL002 (Phase 2 INVOKE-2 trial failed primary endpoint in early AD, October 2024) partnered with AbbVie, and Denali Therapeutics' DNL919/TAK-920 (ATV-TREM2, Phase 1, partnered with Takeda). Vigil's VG-3927 represents the first oral small-molecule TREM2 agonist with Phase 1 PD data showing target engagement and brain penetrance, differentiated from the biologics on convenience and cost. Sanofi gains a complementary disease-modifying mechanism alongside its legacy neurology assets and positioning versus Lilly and Eisai/Biogen in the emerging AD chronic-care market. Upstream pipeline competition also includes Cerevel/AbbVie's GSK-3 inhibitors and various anti-tau antibodies (Eli Lilly zagotenemab, Biogen BIIB080).